Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CEO Sean Duffy sold 8,628 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $21.85, for a total value of $188,521.80. Following the transaction, the chief executive officer owned 411,861 shares of the company’s stock, valued at $8,999,162.85. This represents a 2.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Omada Health Price Performance
Shares of NASDAQ OMDA opened at $24.37 on Friday. The firm has a market capitalization of $1.49 billion, a PE ratio of 487.40 and a beta of 1.73. Omada Health, Inc. has a 1-year low of $10.28 and a 1-year high of $26.92. The business’s fifty day moving average price is $20.87 and its two-hundred day moving average price is $16.43.
Omada Health (NASDAQ:OMDA – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.10. The company had revenue of $87.83 million during the quarter, compared to the consensus estimate of $80.93 million. Omada Health had a net margin of 1.39% and a return on equity of 2.67%. Equities research analysts expect that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Omada Health
Omada Health News Roundup
Here are the key news stories impacting Omada Health this week:
- Positive Sentiment: Q2 results exceeded expectations. Omada reported adjusted earnings of $0.08 per share, compared with analysts’ expectation of a $0.02 loss, while revenue of approximately $87.8 million topped the $80.9 million consensus estimate. The results suggest growth in its digital chronic-care platform is increasingly converting into profitability. Omada Health Q2 earnings analysis
- Positive Sentiment: Several analysts raised their targets. Robert W. Baird lifted its price target from $15 to $25, while maintaining a neutral rating. Other recent targets include $27 from Citizens JMP and $35 from BTIG. The broader analyst consensus remains “Moderate Buy,” with an average target around $25.67–$25.75.
- Positive Sentiment: Institutional ownership increased. Perceptive Advisors and BlackRock reportedly initiated positions, Millennium Management expanded its stake, and Versant Capital Management increased its holdings by more than 300%. These moves may reinforce investor confidence in Omada’s growth outlook.
- Neutral Sentiment: Baird’s neutral stance highlights limited near-term upside. Its $25 target is only modestly above the recent trading level, suggesting the earnings beat and growth prospects may already be substantially reflected in the stock price.
- Negative Sentiment: Multiple senior executives sold shares. CEO Sean Duffy sold 8,628 shares, CFO Steven Cook sold 16,842 shares across two transactions, President Wei-Li Shao sold 8,866 shares, and Chief Accounting Officer Craig Gracey sold 1,042 shares. Although these sales may reflect personal liquidity or compensation planning, concentrated selling near $25 can weigh on sentiment. Omada Health insider trading report
- Negative Sentiment: Valuation risk remains elevated. Omada’s market capitalization is approximately $1.5 billion, while its reported price-to-earnings ratio is above 475. With the shares close to their 52-week high, any slowdown in revenue growth or profitability could prompt profit-taking.
Analysts Set New Price Targets
Several equities research analysts have commented on the stock. BMO Capital Markets restated an “outperform” rating and issued a $24.00 price target on shares of Omada Health in a research note on Friday, August 7th. BTIG Research boosted their price objective on Omada Health from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday. The Goldman Sachs Group reissued a “buy” rating on shares of Omada Health in a report on Friday, May 8th. Morgan Stanley restated an “overweight” rating and issued a $30.00 target price on shares of Omada Health in a research report on Monday, June 22nd. Finally, Citizens Jmp boosted their price target on Omada Health from $21.00 to $27.00 and gave the stock a “market outperform” rating in a research report on Monday, July 20th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Omada Health currently has an average rating of “Moderate Buy” and a consensus target price of $25.75.
View Our Latest Report on OMDA
About Omada Health
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Read More
- Five stocks we like better than Omada Health
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
